<DOC>
	<DOC>NCT01387958</DOC>
	<brief_summary>This is a proof of concept study, designed to look at the safety and antiviral activity of LCQ908 in hepatitis C infected patients.</brief_summary>
	<brief_title>A Two Week Dosing Study to Determine the Safety and Antiviral Activity of LCQ908 in Hepatitis C Patients</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Antiviral Agents</mesh_term>
	<criteria>Written informed consent. Male and female subjects 18 to 65 years of age with hepatitis C infections (genotypes 1, 2 or 3). No prior therapy or inadequate response to therapy for hepatitis C. Weight at least 50 kg and body mass index (BMI) within 18 35 kg/m2. Use of other investigational drugs within at least 30 days of enrollment Women of childbearing potential. Other protocoldefined inclusion/exclusion criteria apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Hepatitis C virus</keyword>
	<keyword>Chronically infected</keyword>
	<keyword>treatment naive</keyword>
	<keyword>non responders to prior therapy</keyword>
</DOC>